Objective:The present study aimed to evaluate the effect of adjuvant growth hormone (GH) therapy in antagonist protocol aiming to improve ovarian response and clinical outcomes of women with poor ovarian response. Methodology:This clinical trial was a single-center study, controlled with equal randomization, which was carried out in Avicenna Infertility Clinic, Tehran, Iran. Totally, 118 patients were randomly allocated to either the intervention or the control group. The intervention group received GH and gonadotropin in gonadotropin-releasing hormone (GnRH) antagonist protocol (GH/GnRHant), while the control group received gonadotropin in GnRH antagonist protocol (GnRHant). Results: The results revealed that the number of days of gonadotropin administration significantly decreased (p-value = 0.040) in the GH/GnRHant group compared to the GnRHant group. Also, our study findings showed that a number of top-quality day 3 embryos and clinical pregnancy rate were higher in the GH/GnRHant group (p-value = 0.007) compared to the GnRHant group (p-value = 0.036). However, there was no significant difference between the two groups in terms of number of received gonadotropin ampoules, number of retrieved MI and MII oocytes, chemical pregnancy rate, ongoing pregnancy rate and live birth rate. Conclusion: These results suggest that adjuvant GH therapy in antagonist protocol in women with a history of poor ovarian response is effective to decrease the number of days of received gonadotropin ampoules and improve pregnancy rate.
Objective:The present study aimed to evaluate the effect of adjuvant growth hormone (GH) therapy in antagonist protocol aiming to improve ovarian response and clinical outcomes of women with poor ovarian response. Methodology:This clinical trial was a single-center study, controlled with equal randomization, which was carried out in Avicenna Infertility Clinic, Tehran, Iran. Totally, 118 patients were randomly allocated to either the intervention or the control group. The intervention group received GH and gonadotropin in gonadotropin-releasing hormone (GnRH) antagonist protocol (GH/GnRHant), while the control group received gonadotropin in GnRH antagonist protocol (GnRHant). Results: The results revealed that the number of days of gonadotropin administration significantly decreased (p-value = 0.040) in the GH/GnRHant group compared to the GnRHant group. Also, our study findings showed that a number of top-quality day 3 embryos and clinical pregnancy rate were higher in the GH/GnRHant group (p-value = 0.007) compared to the GnRHant group (p-value = 0.036). However, there was no significant difference between the two groups in terms of number of received gonadotropin ampoules, number of retrieved MI and MII oocytes, chemical pregnancy rate, ongoing pregnancy rate and live birth rate. Conclusion: These results suggest that adjuvant GH therapy in antagonist protocol in women with a history of poor ovarian response is effective to decrease the number of days of received gonadotropin ampoules and improve pregnancy rate.